



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | | | |
|--|--|--|---|--|--|
| (51) International Patent Classification 5 : A61K 31/57 | | A1 | (11) International Publication Number: WO 91/04030 | | |
| (21) International Application Number: PCT/US90/05452 | | (43) International Publication Date: 4 April 1991 (04.04.91) | | | |
| (22) International Filing Date: 25 September 1990 (25.09.90) | | | | | |
| (30) Priority data: 412,270 25 September 1989 (25.09.89) US | | | | | |
| (71) Applicant: UNIVERSITY OF UTAH [US/US]; Salt Lake City, UT 84112 (US). | | (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent). | | | |
| (72) Inventors: DAYNES, Raymond, A. ; 1747 East Orchard Drive, Salt Lake City, UT 84106 (US). ARANEO, Barbara, A. ; 3880 Arroyo Road, Salt Lake City, UT 84106 (US). | | | | | |
| (74) Agents: CIOTTI, Thomas, E. et al.; Irell & Manella, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US). | | | | | |
| (54) Title: USE OF STEROID HORMONES IN COMPOSITIONS FOR INDUCING T CELL LYMPHOKINE PRODUCTION | | | | | |
| (57) Abstract | | | | | |
| Disclosed is a method for enhancing the production of T cell lymphokines, which comprises exposing T cell lymphocytes which have a potential to make selected T cell lymphokines to an appropriate concentration of at least one particular steroid hormone prior to cellular activation. Also disclosed are applications of the method for clinically diagnosing abnormal interleukin production, maintaining <i>in vitro</i> tissue cultures of T cells, overcoming certain types of immunosuppression caused by elevated GCS levels, caused by endogenous production or exogenous administration, use as a vaccine adjuvant to selectively direct the vaccine-induced immune response down a protective, rather than a potentially pathologic or non-protective, immunologic pathway, as a treatment for naturally occurring aging-related decreases in immune function, as a treatment for stress or trauma-induced decreases in immune function, and as a means to facilitate desensitization to agents to which a warm-blooded animal is allergic. | | | | | |

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|------------------------------|----|--|----|--------------------------|
| AT | Austria | ES | Spain | MC | Monaco |
| AU | Australia | FI | Finland | MG | Madagascar |
| BB | Barbados | FR | France | ML | Mali |
| BE | Belgium | GA | Gabon | MR | Mauritania |
| BF | Burkina Fasso | GB | United Kingdom | MW | Malawi |
| BG | Bulgaria | GR | Greece | NL | Netherlands |
| BJ | Benin | HU | Hungary | NO | Norway |
| BR | Brazil | IT | Italy | RO | Romania |
| CA | Canada | JP | Japan | SD | Sudan |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SE | Sweden |
| CG | Congo | KR | Republic of Korea | SN | Senegal |
| CH | Switzerland | LI | Liechtenstein | SU | Soviet Union |
| CM | Cameroon | LK | Sri Lanka | TD | Chad |
| DE | Germany, Federal Republic of | LU | Luxembourg | TG | Togo |
| DK | Denmark | | | US | United States of America |

-1-

USE OF STEROID HORMONES IN COMPOSITIONS
FOR INDUCING T CELL LYMPHOKINE PRODUCTION

BACKGROUND OF THE INVENTION

Field: The invention relates to regulation of cytokine production, particularly in vitro and in vivo enhancement of lymphokine production by T cell lymphocytes which are exposed to particular types of steroid hormones prior to cellular activation, and applications thereof.

10

State of the Art: It is known that lymphocytes exported from the thymus undergo a series of differentiation events which confer upon them the capacity to recognize and respond to specific peptide antigens presented appropriately in the context of self major histocompatibility complex (MHC) molecules (Bevan, J. Exp. Med., 142:1349 (1975); Zinkernagel et al., J. Exp. Med., 141:1427 (1975)). Mechanistically, thymic maturation is a complex process which includes an irreversible rearrangement of T cell receptor genes (Hedrick et al. Nature, 308:149 (1984); Yanagi et al., Nature, 308:145 (1984)), the cell surface expression of these gene products as a disulfide-linked heterodimer (Meur et al., J. Exp. Med., 158:988 (1983); Kappler et al., Cell, 35:295 (1983)), positive and negative selection processes to provide appropriate restriction and avoidance of self reactivity (Von Boehmer et al., Immunol. Rev., 101:5 (1988)), and the synthesis and expression of CD4 or CD8 as accessory adhesion molecules (Bierer et al., Ann. Rev. Immunol., 7:579 (1989); Dembic et al., Nature, 320:232

-2-

(1986)). Microenvironmental influences within the thymus play an essential role in the fidelity of this process.

Subsequent to leaving the thymic microenvironment,
5 mature T lymphocytes gain access to the recirculating T cell pool where they move freely via the blood between mucosal and nonmucosal lymphoid compartments in the mammalian host (Hamann et al., Immunol. Rev., 108:19
10 (1989)). T-lymphocyte expression of lymphoid tissue-specific homing receptors, which are complementary for vascular addressins on high endothelial venules
15 present in Peyer's patches and peripheral lymph nodes, provide a biochemical means for selectivity to this recirculation process (Hamann et al., Immunol. Rev.,
108:19 (1989)). Non-activated lymphocytes can move freely
20 between mucosal and nonmucosal lymphoid tissues due to the presence of both types of homing receptors on their plasma membranes (Pals et al. Immunol., Rev., 108:111 (1989)).
25 Effector lymphocytes, and antigen-activated immunoblasts which are stimulated in a particular site in the body, however, exhibit a far more selective migratory behavior.
These cells move primarily to tissues originally involved
30 in antigen exposure and cellular activation (Hamann et al., Immunol. Rev., 108:19 (1989); Pals et al., Immunol. Rev., 108:111 (1989)).

35

An immune response is initiated following T cell recognition of antigen peptides in the context of self MHC

-3-

molecules and generally takes place in one of the host's secondary lymphoid compartments. Cellular activation is triggered by the binding of antigen to the T cell receptor (TCR), forming an antigen/TCR complex which transduces the antigen-specific extracellular stimulation across the plasma membrane, and generates intracellular signals which include the activation of protein kinase C and the increases in intracellular calcium (Alcover et al., Immunol. Rev., 95:5 (1987); Gelfand et al., Immunol. Rev., 95:59 (1987)). While signal transduction can lead to T cell unresponsiveness (Mueller et al., Ann. Rev. Immunol., 7:445 (1989)), positive signal transduction events trigger a series of additional biochemical processes. One consequence of this activation is the stimulated production of a number of biologically active molecules which are collectively termed lymphokines (Alcover et al., Immunol. Rev., 95:5 (1987); Gelfand et al., Immunol. Rev., 95:59 (1987)).

25

The lymphokines, many of which function primarily through autocrine and paracrine mechanisms, serve to mediate numerous effector functions controlled by T cells through their capacity to regulate cellular proliferation, differentiation and maturation events in lymphocytes, plus other hematopoietic and somatic tissue cells (Paul, Cell, 30 35 57:521 (1989)).

-4-

Each of the various types of lymphokines exhibit pleiotropic activities, dependent upon the specific type of cellular targets being stimulated. The biological evaluation of recombinant forms of specific lymphokines 5 has determined that individual species can possess both distinct and overlapping cellular activities (Paul, Cell, 57:521 (1989); Mossman et al., Ann. Rev. Immunol., 7:145 10 (1989)). Interleukin-2 (IL-2) and interleukin-4 (IL-4), for example, share the capacity to facilitate T cell growth but are disparate in their relative contribution to cellular and humoral immune responses. Cloned T cell 15 lines, restricted in their capacity to produce individual species of lymphokines, have been described which demonstrate unique capabilities in serving as effector cells or helper cells for various types of immune 20 responses (Paul, Cell, 57:521 (1989); Mossman et al., Ann. Rev. Immunol., 7:145 (1989); Hayakawa et al., J. Exp Med., 168:1825 (1988)).

25

Immunosuppression in animals can result from a depressed capacity to produce species of lymphokines which are essential to the development of protective forms of 30 immunity. Imbalances between various types of lymphokines, where species of lymphokines capable of promoting one form of immune response exhibit enhanced 35 production, while those lymphokines needed to promote protective forms of immunity are suppressed, can also lead to immunosuppression. It is known that animals may be

-5-

immunosuppressed as a consequence of endogenous elevations in adrenal glucocorticosteroid (GCS) levels. This condition could result from viral infections, certain bacterial infections, certain parasitic infections,
5 cancer, some autoimmune syndromes, stress, trauma, post-surgical trauma, burn trauma or as a secondary consequence to any clinical condition which causes an elevated production of interleukin-1 (IL-1). Plasma GCS
10 levels can also be elevated exogenously as a consequence of therapeutic treatment for a variety of clinical conditions. It is also well known that certain essential
15 functions of the immune system decline with age, a situation which correlates with elevations in adrenal output of GCS and depressions in production of other types
of adrenal steroid hormones.

20

Known pharmaceutical products and therapeutic methods for treating immunosuppressed animals having depressions or imbalances in their ability to produce interleukins
25 have focused on the production and purification of IL-2 by activated T cells, or the production of IL-2 through genetic engineering techniques, followed by the
30 therapeutic administration of this IL-2 or IL-2 administration with a muramyldipeptide in an attempt to restore normal propagation of T cells. Illustrative of such prior art are the disclosures of U.S. Patent No.
35 4,661,447 issued April 28, 1987 to Fabricius et al., U.S. Patent No. 4,780,313 issued October 25, 1988 to Koichiro

-6-

et al. and U.S. Patent No. 4,789,658 issued December 6, 1988 to Yoshimoto et al. The side effects of therapeutic approaches of the prior art of systemic administration of recombinant IL-2 are numerous. Such side effects include 5 fever, hypotension, hepatic and renal failure, myocardial infarctions, capillary leak syndrome, and massive edema (Dinatello et al., New England J. of Med., 317:940 (1987)).

10

Also disclosed in the prior art is the therapeutic use of the adrenal androgen steroid dehydroepiandrosterone (DHEA) to treat maladies such as diabetes, dry skin, 15 ocular hypertension, obesity, and retroviral infections. Illustrative of such prior art teachings are the disclosures of U.S. Patent No. 4,395,408 issued July 26, 20 1983 to Torelli et al., U.S. Patent No. 4,518,595 issued May 21, 1985 to Coleman et al., U.S. Patent No. 4,542,129 issued September 17, 1985 to Orentreich, U.S. Patent No. 4,617,299 issued October 14, 1986 to Knepper, U.S. Patent 25 No. 4,628,052 issued December 9, 1986 to Peat, U.S. Patent No. 4,666,898 issued May 19, 1987 to Coleman et al., European Patent Application No. 0 133 995 A2 dated February 8, 1984 (inventor: Schwartz et al.), and UK 30 Patent Application No. GB 2 204 237 A dated April 14, 1988 (inventor: Prendergast).

-7-

SUMMARY OF THE INVENTION

Objectives: It is an objective of the invention to provide a method for enhancing the biosynthesis of selected lymphokines by activated T cells. Another objective of the invention is to enhance immune functions in warm blooded animals by restoring their capacity to naturally produce physiological concentrations of these lymphokines with a minimization of side effects. Further objectives of the invention are to provide applications of the method for clinically diagnosing deficiencies of interleukin production, maintaining in vitro tissue cultures of T cells, and overcoming certain types of immunosuppression caused by elevated GCS levels, caused by endogenous production or exogenous administration. Final objectives of the invention are to provide applications of the method as a vaccine adjuvant to selectively direct the vaccine-induced immune response down a protective, rather than a potentially pathologic or non-protective, immunologic pathway, as a treatment for naturally occurring aging-related decreases in immune function, as a treatment for stress or trauma-induced decreases in immune function, and as a means to facilitate desensitization to agents to which a warm-blooded animal is allergic.

Features: In the accomplishment of the foregoing objectives of the invention, T cell lymphocytes which have a potential to make selected T cell lymphokines are

-8-

exposed to particular types of steroid hormones prior to activation. This exposure results in an enhanced cellular potential for production of certain T cell lymphokines, and, following cellular activation, if the concentration 5 of the particular steroid hormone is appropriate, the biosynthesis and secretion of certain T cell lymphokines will be maximized.

10

In another aspect of the invention, a diagnostic test for evaluating lymphokine production deficiencies is accomplished by qualitatively and quantitatively comparing 15 the lymphokine production of non-exposed and activated lymphocytes with the lymphokine production of exposed and activated lymphocytes in vitro. In another aspect of the invention, the method is utilized as a T cell tissue 20 culture maintenance supplement to optimize their potential for T cell growth factor (TCGF) production, thereby maximizing the proliferation of the cultured T cells.

25

In yet another aspect of the invention, the method is utilized as a therapeutic approach for treating immune system depression resulting from elevated levels of GCS, 30 either endogenously produced or exogenously administered, and as a therapy for reversing the age related decline in the biosynthesis of certain T cell lymphokines. In final 35 aspects of the invention, the method is utilized as an adjuvant with vaccines to selectively direct the host immune responses toward protective, rather than pathologic

-9-

or non-protective, pathways. This includes the possibility of employing the method to facilitate the desensitization to specific antigens in individuals with allergies.

5

DRAWING

10 Fig. 1A is the dose response curve for DHEA of example 1;

15 Fig. 1B is the dose response curve for DHEA-S of example 1;

20 Fig. 2A presents the lymphokine response of DHEA and Corticosterone treated normal lymphocytes of example 2;

25 Fig. 2B presents the lymphokine response of DHEA and Dexamethasone (DEX) treated OVA/2 of example 2;

Fig. 2C presents the lymphokine response of DHEA and DEX treated OVA/3 of example 2;

30 Fig. 3 presents the lymphokine response of DHEA or DHEA-S treated animals;

35 Fig. 4A presents the experimental results of example 4A;

-10-

Fig. 4B presents the experimental results of example
4B;

Fig. 5A is the dose response curve for DEX of example
5 5;

Fig. 5B is the dose response curve for Corticosterone
10 of example 5;

Fig. 5C is the dose response curve for 1,25 dihydroxy
vitamin D3 ($1,25(\text{OH})_2\text{D}_3$) of example 5;

15

Fig. 6A presents the results of example 6 wherein GCS
is used as a vaccine adjuvant;

20

Fig. 6B presents the results of example 6 wherein DHEA
and $1,25(\text{OH})_2\text{D}_3$ are used as vaccine adjuvants;

25

Fig. 7A presents the age-associated changes in
lymphokine production in mice demonstrated in example 7;
and

30

Fig. 7B presents the restoration of lymphokine
production in old mice by DHEA demonstrated in example 7.

35

-11-

DETAILED DESCRIPTION

The invention is a method for enhancing or maximizing the production of T cell lymphokines, which comprises
5 exposing T cell lymphocytes which have a potential to make selected T cell lymphokines to appropriate concentrations of particular steroid hormones prior to activation. The 10 particular steroid hormone to which the T cell lymphocyte is exposed depends upon the lymphokine which is selected for enhancement or maximized production. The method works in vitro and in vivo in warm blooded animals which host 15 the T cell lymphocytes. If the T cell lymphocytes are in a warm blooded animal, the exposure can be parenteral, transdermal or transmucosal.

20 As mentioned above, GCS have long been known as immunosuppressors. In accordance with the invention and contrary to the prior art, it has been found that 25 pre-cellular activation exposure of T cell lymphocytes having a potential to make IL-4 to various types of natural and synthetic GCS at physiologic and pharmacologic concentrations results in the enhancement of IL-4 30 production. It has also been found that only at pharmacologic concentrations GCS depress the production of IL-2 and gamma interferon (g-IFN), while enhancing the 35 production of IL-4. At physiologic concentrations, GCS enhance IL-4 production and have no effect on IL-2 and g-IFN production. Hydrocortisone, DEX and corticosterone

-12-

are some of the GCS which work in accordance with this aspect of the invention.


Also in accordance with the invention, the steroid
5 $1,25(\text{OH})_2\text{D}_3$ enhances the production of IL-4 at physiologic and pharmacologic dose levels and, like GCS, inhibits IL-2 and g-IFN production at pharmacologic dose levels.

10

In further accordance with the invention, exposing T cell lymphocytes which have a potential to make selected T 15 cell lymphokines to DHEA or a DHEA cogener prior to activation enhances the production of IL-2 and g-IFN. DHEA cogeners which are useful in the invention have the following structure:

20

25



30

35

-13-

in which R is hydrogen in alpha or beta configuration or nothing, resulting in a double bond between carbon atoms 5 and 6; R₁ is hydrogen or bromine or fluorine in alpha configuration; and R₂ is oxygen or methyl ketone (-COCH₃).
5

The selected steroid hormones may be administered to warm blooded animals through pre-cursor substances which
10 are then metabolized to the steroid hormones. For instance, 25 hydroxy vitamin D₃ may be administered (preferably orally or by injection) and metabolized to 15 1,25 (OH)₂D₃. Also, the sulfanated form of DHEA (DHEA-S) may also be used in the method provided the T cell lymphocytes are in a warm blooded host and the DHEA-S is administered to the warm blooded host in a fashion
20 (preferably orally or by injection) in which it may then be metabolized to DHEA by tissue-associated DHEA-sulfatases.
25

The simultaneous enhancement or maximization of the production of more than one T cell lymphokine may be achieved by exposing the T cell lymphocyte to more than 30 one steroid hormone prior to activation. The exposure to more than one steroid hormone can be done simultaneously or sequentially. The concentration of each of the steroid hormones should be balanced to achieve the desired 35 enhancing effects. For example, if it were desirous to enhance the production of IL-2, g-IFN and IL-4, the T cell

-14-

lymphocytes could be exposed to physiologic or pharmacologic levels of DHEA and a physiologic level of GCS. This would avoid the IL-2 and g-IFN depression which is characteristic of a pharmacologic level of GCS.

5

Evidence derived from experimental and clinical observations indicates that immunologic reactions elicited to either simple or complex antigens often manifest as a balanced heterogeneous blend of both cellular and humoral components, with the fractional contribution of any individual type of effector mechanism oftentimes dominating the overall response. This level of heterogeneity, which is both quantitatively and qualitatively based, is essential to the development of a protective immune response (Parish, Transpl. Rev. 13:35 (1972); Katsura, Immunol. 32:227 (1977)). Alterations to this natural balance, whether caused by genetic or physiologic changes, can lead to a depressed capacity to elicit protective immune responses (Coutelier et al., J. J. Exp. Med. 165:64 (1987); Ogilvie et al., Cellular and Humoral Mechanisms in Anaphylaxis and Allergy, R. Karger, New York, p. 378 (1969); and Mayrhofer et al., Immunol. 30 37:145 (1979)), and might also lead to immunologic responses having pathologic consequences (Mayrhofer et al., Immunol. 37:145 (1979); Locksley et al., Ann. Inst. Pasteur/Immunol. 138:744 (1987); and Tite et al., J. Immunol. 35 139:2892 (1987)).

-15-

Administration of steroid hormones in accordance with the invention would be useful in treating such immune system imbalances in warm blooded animals. Characteristic of this type of immunosuppression are abnormal levels of selected steroid hormones or abnormal ratios of selected steroid hormones. Immunosuppression in warm blooded animals may be mediated by endogenously or exogenously elevated GCS levels. Elevated GCS levels can result from a variety of causes including, but not limited to, viral infections, certain bacterial infections, certain parasitic infections, cancer, some autoimmune syndromes, stress, trauma, post-surgical trauma, burn trauma, as a secondary consequence to any clinical condition which causes an elevated production of IL-1, or therapeutic treatment for a variety of clinical conditions. The elevated GCS levels can result in an imbalance in the production of essential interleukins. The normal balance of essential interleukin production may be restored by administration of steroid hormones of the appropriate types and combination in accordance with the invention.

Additionally, if it were known that elevated GCS levels were the result of certain behavior or maladies, administration of antagonistic steroid hormones in accordance with the invention could be used as a prophylaxis prior to the onset of the elevation in GCS levels and resultant immunosuppression. For instance, there is a bovine malady commonly known as "Shipping

-16-

"Fever" wherein there is a high rate of morbidity and mortality associated with the stress induced by long distance bovine shipment. This stress is associated with chronic increased levels of GCS. Prophylactic 5 administration of steroid hormones in accordance with the invention prior to bovine shipment would counteract the immunosuppressive effects of the chronically elevated GCS 10 levels, and, therefore, reduce the risk of these animals to infectious agents.

The invention may also be used as a diagnostic tool in 15 evaluating lymphokine production deficiency. In this application T cell lymphokine production of a first group of T cell lymphocytes which have a potential to make selected T cell lymphokines after T cell lymphocyte 20 activation is measured. A second group of the same type of T cell lymphocytes is exposed to a particular steroid hormone prior to T cell lymphocyte activation. The 25 selected T cell lymphokine production of the second group of T cell lymphocytes is then measured after activation. The amount of T cell lymphokine production of the two groups of T cell lymphokines are compared. The 30 sensitivity of the diagnostic tool is maximized when the amount of the particular steroid hormone to which the second group of T cell lymphocytes is exposed is sufficient to maximize the production of the T cell 35 lymphokines which the particular steroid hormone enhances. If the T cell lymphokine measured is IL-2 or

-17-

g-IFN, the preferable steroid hormone may be selected from the group DHEA or a DHEA cogener having the structure recited above. If the T cell lymphokine measured is IL-4, the preferable steroid hormone may be selected from the 5 group GCS or $1,25\text{ (OH)}_2\text{D}3$.

Another application of the invention is to use the method as a vaccine adjuvant to selectively direct the 10 vaccine-induced immune response down a protective, rather than a potentially pathological or non-protective, immunologic pathway. Warm blooded animals, when 15 immunized, will produce an immunologic response in which certain lymphokines are produced. When warm blooded animals are immunized with the same immunizing agent and a selected steroid hormone is administered in accordance 20 with the invention prior to or contemporaneously with vaccination, certain lymphokine responses are greatly enhanced, directing the vaccine induced response down a protective immunologic pathway. Typical methods of 25 administering the steroid hormone in this application of the invention include implants, mixing the steroid hormone with the immunizing agent, and topically applying the 30 steroid hormone to skin sites above the site of vaccination. When it is desirous to promote cellular immunity, preferable vaccine adjuvants are steroid hormones selected from the group consisting of DHEA and 35 DHEA cogeners having the structure recited above. When it is desirous to promote humoral immune responses,

-18-

preferable vaccine adjuvants are steroid hormones

selected from the group consisting of GCS or 1,25

(OH)₂D₃.

5 It is also believed that the invention can be used as
a means to facilitate desensitization to agents to which a
warm blooded animal is allergic. Desensitization of a
10 warm blooded animal to an allergic agent is dependent upon
induction by an allergic host of a secondary type of
immunologic response not involving IgE. Since the
15 administration of steroid hormones in accordance with the
invention has proven to selectively promote immunologic
responses that do not involve IgE, the method of the
invention should work as an adjuvant to desensitization
techniques.

20

Another application of the invention is to treat
naturally occurring age-related decreases in immune
function. Associated with age related decline in immune
25 function is a decrease in the production of certain
lymphokines. Treatment of aging, warm blooded animals
with steroid hormones by the method of the invention
30 substantially restores the production of selected
lymphokines. For example, it has been found that
treatment of aging mice with DHEA enhances the capacity of
35 the animal's T cells to produce IL-2 and g-IFN to levels
nearly equivalent to young control mice.

-19-

The invention and applications thereof are further described in connection with the following examples, which are intended to illustrate the invention, but not to limit the scope thereof.

5

Example 1

10 DHEA enhances IL-2 production by activated murine T
cells. In this experiment the capacity of DHEA and DHEA-S
to alter the production of IL-2 and IL-4 following in
vitro lymphocyte treatment or exposure was evaluated.
15 DHEA significantly enhanced the production of IL-2 over a
wide dose range, and DHEA-S, over the same dose range, had
no effect on IL-2 and IL-4 production. Fig. 1A is the
dose response curve of DHEA and Fig. 1B is the dose
20 reponse curve of DHEA-S developed in this experiment.

25 Spleen cells obtained from normal BALB/c mice were
prepared as a single cell suspension at a concentration of
 1×10^7 cells/ml in RPMI 1640 supplemented with 2 mM
L-glutamine, 5×10^{-5} M 2-mercaptoethanol, 20 ug/ml
gentamycin-sulfate, and 1% Nutridona-NS
30 (Boehringer-Mannheim). Individual aliquots of cells were
then pulsed for 30 minutes at 37°C with the indicated
concentrations of DHEA or DHEA-S. After pulsing, the
cells were washed several times in balanced salt solution,
35 resuspended in fresh medium, and then dispensed into
24-well culture plates with a stimulatory concentration of

-20-

anti-CD3 (Leo et al. Proc. Natl. Acad. Sci. USA, 84:1374 (1987)). After a 24-hour incubation period, culture supernatants were harvested for assessment of IL-2 and IL-4 activity using the method of Mossman (J. Immunol. 5 Meth. 65:55 (1983)). In this experiment, 100% control titers of IL-2 and IL-4 from normal stimulated splenocytes in Fig. 1A were 640 and 160 units/ml, respectively. For 10 control splenocytes from Fig. 1B, 100% control titers of IL-2 and IL-4 were 2560 and 320 units/ml, respectively.

This same experiment was repeated to assay for g-IFN 15 production. A dose response curve similar to that reported in Fig. 1A for DHEA was obtained for g-IFN.

This same experiment was performed using the DHEA 20 cogener 16 alpha bromo DHEA in place of DHEA. A dose response curve similar to that reported in Fig. 1A was obtained for 16 alpha bromo DHEA.

25

Example 2

DHEA enhances IL-2 production in GCS-treated normal
30 splenocytes and cloned T cell lines. In this series of experiments the capacity of DHEA to facilitate a reversal of glucocorticoid-induced suppression of IL-2 production
35 by either normal murine lymphocytes, or cloned T cell

-21-

lines with similarities to either Th1-type or Th2-type helper T cells was evaluated.

Referring to Fig. 2A exposure of splenocytes to the
5 effects of Corticosterone (10^{-7} M) greatly reduced the capacity of cells to produce IL-2 subsequent to activation with anti-CD3. DHEA treatment alone augmented IL-2 production. Lymphocytes exposed to Corticosterone and 10 DHEA, followed by their activation in vitro, produced normal or enhanced levels of IL-2 and enhanced levels of IL-4.
15

Referring to Fig. 2B and Fig. 2C, OVA/2 (an ovalbumin (OVA)-specific cloned T cell line with characteristics similar to Th2-type cells), and OVA/3 (a cloned T cell 20 line with characteristics similar to Th1-type cells), were exposed in vitro to the effects of DHEA and/or glucocorticoids prior to their culture with antigen and 25 syngeneic antigen-presenting cells. As shown in Fig. 2C, DHEA treatment of OVA/3 greatly augmented the capacity of this cell line to produce IL-2, while exposure to DEX resulted in an IL-4 dominant phenotype, similar to what is 30 observed with Th2-type clones. Treatment of OVA/3 with DEX followed by DHEA, resulted in a marked elevation in IL-2 production with only a minimal enhancement of IL-4.
35 As shown in Fig. 2B, the effects of steroid treatment on the capacity of OVA/2 to produce TCGF gave comparable results. DHEA exposure of this T cell clone was capable

-22-

of shifting the pattern of TCGF production from a Th2-like to a Th1-like phenotype (IL-2 dominant), while DEX treatment alone augmented IL-4 production following activation in vitro with OVA. Treatment of OVA/2 with 5 both DEX and DHEA caused an enhanced capacity to produce both IL-2 and IL-4.

10 Single cell suspensions of normal murine spleen cells were prepared in Nutridoma-supplemented complete RPMI at 10^7 cells/ml. They were then pulsed with 10^{-7} M Corticosterone and/or 10^{-8} M DHEA as described in Fig. 15 2A. After several washes, the cells were stimulated with anti-CD3. The enhancement of IL-2 production by DHEA exposed normal splenocytes is reported in Fig. 2A. Fig. 2C and Fig. 2D describe the regulation of lymphokine 20 production by two ovalbumin (OVA)-specific cloned T cell lines. The OVA-specific T cell clones were derived from nylon-wool enriched splenic T cells from OVA-immunized 25 (C3H x C57/B6)F₁ mice using the method of Berzofsky (J. Immunol. 35:2628 (1985)). OVA/3 and OVA/2 cell lines were derived from different clonings, each having distinct 30 patterns of lymphokine production. Culture conditions and assay procedures for IL-2 and IL-4 are as in Example 1.

Example 3

35

A single injection of mice with DHEA or DHEAS enhanced the biosynthesis of IL-2 by activated lymphoid cells. In

-23-

this experiment the effects of in vivo administration of DHEA and DHEA-S on IL-2 and IL-4 biosynthesis are demonstrated. Groups of (C3H x BL/6)F₁ mice were given a single intraperitoneal injection of 100 ug DHEA or 5 DHEAS. After three days, spleen cells from the treated groups, plus spleen cells from an untreated age-matched control group, were prepared for culture as described in Example 1. The relative titers of IL-2 and IL-4 in the 10 24-hour culture supernatants were determined in the presence of anti-IL-2, or anti-IL-4, both anti-IL-2 and anti-IL-4, or no blocking antibodies. The assay was read 15 visually. Non-activated cultured lymphoid cells produced undetectable (less than 2 Units) of either IL-2 or IL-4.

Example 4A

20

DHEA enhances IL-2 production in splenocytes from corticosterone-treated mice. This experiment demonstrates 25 the reversal of the inhibitory effects caused by chronic glucocorticoid administration to normal mice in vivo on the capacity of their T cells to produce IL-2. A short pulse with DHEA (10^{-8}) in vitro prior to lymphocyte 30 activation caused a significant enhancement of IL-2 production. Under these conditions, the glucocorticoid-induced augmentation in IL-4 synthesis was 35 not affected, resulting in a population of lymphoid cells capable of producing high levels of both IL-2 and IL-4.

Biodegradable pellets (Innovative Research, Inc.)

-24-

containing corticosterone and designed to deliver this steroid at a dose of 5 ug/hr were implanted subcutaneously into (C3H X B46) F₁ mice 72 hours prior to the harvesting of the splenocytes for culture. Culture and 5 assay procedures are as described in Example 1. The results are presented in Fig. 4A.

10

Example 4B

DHEA in vivo enhances IL-2 production in mice with and without corticosterone treatment. This experiment 15 demonstrates that DHEA administered in vivo influences the profile of TCGF produced by splenocytes isolated from these treated animals. The stimulation of splenocytes isolated from normal animals consistently gave a standard 20 pattern of TCGF production where IL-2 dominated over IL-4. Lymphocytes isolated from corticosterone-treated animals (5 ug/hr) demonstrated a marked reversal of this 25 pattern where IL-4 consistently represented the dominant TCGF. Similar to what is observed following an in vitro treatment with this androgen steroid, activated splenocytes from DHEA-treated animals (5 ug/hr) exhibited 30 an enhancement in IL-2 production. Under conditions where both steroids were therapeutically elevated in vivo, it was found that isolated splenocytes from these animals 35 produced enhanced levels of both IL-2 and IL-4 subsequent to their activation with anti-CD3 in vitro.

-25-

Biodegradable pellets (Innovative Research, Inc.) containing corticosterone or DHEA that deliver their drugs 5 ug/hour were implanted subcutaneously into three separate groups of BALB/C mice 72 hours prior to 5 harvesting and preparation of spleen cells. Single cell preparations of splenocytes from each group were cultured as described in Example 1 and stimulated with the polyclonal T cell mitogens anti-CD3. After 24 hours, 10 culture supernatants were collected and assayed for IL-2 and IL-4 activity as described in Example 1. The experimental results are reported in Fig. 4B.

15

Example 5

20 Dose-dependent inhibition of IL-2 and g-IFN with a simultaneous activation of IL-4 by glucocorticoids and 1,25 dihydroxyvitamin D3. This experiment demonstrates that glucocorticosteroids and 1,25(OH)₂D₃, at 25 physiological dose levels, enhance the production of IL-4 without effecting IL-2 and g-IFN production, and, at pharmacological dose levels, enhance the production of 30 IL-4 and inhibit the production of IL-2 and g-IFN. (C3H x BL/6)F₁ mice were immunized by subcutaneous immunization in the flank region with 100 ug OVA/CFA. Two weeks later, single cell suspensions of spleens were prepared in 35 Nutridoma-supplemented, complete RPMI at 1 x 10⁷ cells/ml. Referring to Fig. 5A, a portion of the cells were subdivided into groups containing the indicated

-26-

concentrations of DEX and incubated for 30 minutes at 37°C. Referring to Fig. 5B, cells were treated with corticosterone. Referring to Fig. 5C, cells were treated with 1,25(OH)₂D₃. After multiple washes, cells were
5 dispensed into culture wells in 1ml volumes at 1 x 10⁷ cells/ml with either no antigen or 100 ug OVA. After a 24-hour incubation period in a humidified CO₂ incubator,
10 the culture supernatants were harvested for assessment of IL-2 and IL-4 activity using a modification of the method of Mosmann (J. Immunol Meth., 65:55 (1983)). g-IFN was evaluated using a modification of the method of Green
15 (Green et al. J. Clin. Microbiol., 12:433 (1980)). All groups cultured without antigen produced less than 1 Unit IL-2 or IL-4 and no detectable g-IFN.

20

Example 6

In this series of experiments the use of the invention
25 as a vaccine adjuvant is demonstrated.

T cells from corticosterone-treated mice produce low titers of IL-2 and elevated titers of IL-4 in vitro. C3H
30 mice received implants of biodegradable corticosterone pellets designed to deliver steroid at a rate of 5 or 10 ug/hour. The day after implantation, both the steroid treated groups and a normal control group of mice were
35 immunized in the hind footpads with 100 ug OVA in CFA. Ten days after immunization, the draining lymph nodes and

-27-

spleens from all groups were prepared for culture. Lymph node cells were stimulated with 100 ug OVA. Culture supernatants were assayed for IL-2 and IL-4 activity after 24 hours using the HT-2 bioassay. The experimental 5 results are reported in Fig. 6A. Similar alterations in the ability of antigen-activated T cells to product IL-2 and IL-4 were observed when the steroid hormone was mixed with the immunizing antigen, or topically applied to skin 10 sites above the site of vaccination.

T cells from 1,25-dihydroxyvitamin D3-treated mice
15 produce low titers of IL-2 and elevated titers of IL-4 in
vitro. T cells from DHEA-treated mice produce elevated
titers of IL-2 in vitro. C3H mice received implants of
20 biodegradable DHEA or $1,25(\text{OH})_2\text{D}_3$ pellets designed to
deliver steroid at a rate of 5 and 10 ug/hour,
respectively. Three days after implantation, both the
steroid treated groups and a normal control group of mice
25 were immunized in the hind footpads with 100 mg OVA in
CFA. Ten days after immunization, the draining lymph
nodes and spleens from all groups were prepared for
culture. Lymph node cells were stimulated with 100 ug
30 OVA. Culture supernatants were assayed for IL-2 and IL-4
activity after 24 hours using the HT-2 bioassay. The
experimental results are reported in Fig. 6B. Similar
alterations in the ability of antigen-activated T cells to
35 produce IL-2 and IL-4 were observed when the steroid
hormone was mixed with the immunizing antigen, or

-28-

topically applied to skin sites above the site of vaccination.

Example 7

5

This series of experiments demonstrates age related decline in certain lymphokine production in warm blooded animals and restoration of certain lymphokine production 10 in old warm blooded animals by appropriate steroid hormone treatment in accordance with the invention. The particular lymphokines assayed are IL-2, IL-4 and g-IFN 15 and the steroid hormone administered is DHEA.

Aging is associated with a reduction in the ability of activated T cells to produce IL-2, and a parallel increase 20 in the production of IL-4. Referring to Fig. 7A, (C3H x BL/6)F₁ mice of the indicated ages were sacrificed and their spleen cells prepared for culture with mitogen, 25 anti-CD3. Culture supernatants were harvested and evaluated for the relative contribution of IL-2 and IL-4 using the HT-2 bioassay. Non-activated cells product less than 1 Unit of either IL-2 or IL-4.

30

DHEA treatment of old mice enhances the capacity of 35 their T cells to produce IL-2 and g-IFN following activation to levels nearly equivalent to young control mice. Referring to Fig. 7B, both young (6 mos.) and old (16 mos.) mice were implanted with DHEA pellets at a dose

-29-

of 5 ug/hour. After three days, DHEA groups and control age-matched groups were sacrificed and their spleen cells prepared for culture with the mitogen anti-CD3. Culture supernatants were harvested and evaluated for the relative contribution of IL-2 and IL-4 using the HT-2 bioassay, and for g-IFN using the assay of Green. Non-activated cells produce less than 1 Unit of either IL-2 or IL-4 and no detectable g-IFN. Similar enhancement in the capacity of lymphocytes derived from old mice to produce IL-2 was observed following a direct exposure in vitro to DHEA (10^{-9} M - 10^{-7} M).

15

Whereas this invention is here illustrated and described with specific reference to an embodiment thereof presently contemplated as the best mode in carrying out such invention, it is to be understood that various changes may be made in adapting the invention to different embodiments without departing from the broad inventive concepts disclosed herein and comprehended by the claims that follow:

30

35

-30-

Claims

1. Use of a steroid hormone for the
5 manufacture of a composition for inducing the production
of T cell lymphokines by T cells which have the potential
to make such lymphokines.


10 2. The use of a steroid hormone according to
claim 1 wherein the induction is for the purpose of
treating stress-induced immunosuppression.

15 3. The use of a steroid hormone according to
claim 2 wherein the induction is for the purpose of
treating stress-induced immunosuppression associated with
elevated levels of adrenal glucocorticosteroid.

20 4. The use of a steroid hormone according to
claim 1 wherein the steroid hormone is a
glucocorticosteroid, 1,25-dihydroxy vitamin D₃,
dehydroepiandrosterone (DHEA), or a DHEA congener.

25 5. The use of a steroid hormone according to
claim 4 wherein the DHEA congener is of the formula:

30



-31-

6. The use of a steroid hormone according to
claim 1 wherein the steroid hormone is a
glucocorticosteroid or 1,25-dihydroxy vitamin D₃ or a
5 precursor thereof and the lymphokine is IL-4.

7. The use of a steroid hormone according to
claim 1 wherein the steroid hormone is
dehydroepiandrosterone (DHEA) or a DHEA congener and the
10 lymphokine is IL-2 or gamma IFN.

8. The use of a steroid hormone according to
claim 7 wherein the DHEA is the sulfated form of DHEA.

15 9. The use of a steroid hormone according to
claim 1, 2, 3, 4, 5, 6, or 7 wherein the composition is
designed for parenteral, transdermal, or transmucosal
administration.

20 10. The use of a steroid hormone according to
claim 7 or 8 wherein the amount of steroid hormone in the
composition is sufficient to permit the T cells to be
exposed to a DHEA concentration between 10⁻¹² M and
10⁻⁶ M.

25 11. The use of a steroid hormone according to
claim 6 wherein the precursor is 25-hydroxy vitamin D₃.

30 12. The use of a steroid hormone according to
claim 6 wherein the steroid hormone is 1,25-dihydroxy
vitamin D₃ or a precursor thereof and the amount of
steroid hormone in the composition is sufficient to

-32-

permit the T cells to be exposed to a 1,25-dihydroxy vitamin D₃ concentration between 10⁻¹² M and 10⁻⁷ M.

5 13. The use of a steroid hormone according to claim 6 wherein the glucocorticosteroid is dexamethasone, hydrocortisone, cortisol or corticosterone.

10 14. The use of a steroid hormone according to claim 6 or 13 wherein the steroid hormone is a glucocorticosteroid and the amount of glucocorticosteroid in the composition is sufficient to permit the T cells to be exposed to a glucocorticosteroid concentration between 10⁻¹⁴ M and 10⁻⁷ M.

15 15. Use of a steroid hormone according to claim 1 wherein the induction is for the purpose of directing a vaccine-induced immune response down a protective immunologic pathway.

20 16. Use of a steroid hormone according to claim 1, 7, 8, or 10 wherein the induction is for the purpose of treating naturally occurring age-related decline in immune function.

25 17. A method for evaluating lymphokine production, which comprises measuring selected T cell lymphokine production of a first group of T cell lymphocytes which have a potential to make the selected T cell lymphokines after cellular activation, exposing a 30 second group of the T cell lymphocytes which have a potential to make the selected T cell lymphokines to at least one steroid hormone prior to cellular activation,

-33-

measuring the selected T cell lymphokine production of
the second group of T cell lymphocytes which have a
potential to make the selected T cell lymphokines after
cellular activation, and comparing the amount and types
5 of T cell lymphokine production of the first group with
the amount and types of T cell lymphokine production of
the second group.

10 18. A method for evaluating an interleukin
production as recited in Claim 17, wherein the steroid
hormone is DHEA and the selected T cell lymphokines are
selected from the group consisting of interleukin-2 and
gamma interferon.

15 19. A method for evaluating an interleukin
production as recited in Claim 17, wherein the steroid
hormone is 1,25-dihydroxy vitamin D₃ or a
glucocorticosteroid and the selected T cell lymphokine is
interleukin-4.

20 20. Use of a steroid hormone according to
claim 1 wherein the steroid hormone is one that induces
IL-4 production by T cells and the induction is for the
purpose of allergen desensitization.

25

1 / 8




FIG. 1A








FIG. 1B

SUBSTITUTE SHEET

2 / 8

***FIG. 2A******FIG. 2B***

3 / 8

**FIG. 2C****FIG. 3****SUBSTITUTE SHEET**

4 / 8




FIG. 4A
1/dilution




FIG. 4B
1/dilution

SUBSTITUTE SHEET

5 / 8




FIG. 5A

FIG. 5B

6 / 8








FIG. 5C

SUBSTITUTE SHEET

7 / 8

*FIG. 6A**FIG. 6B***SUBSTITUTE SHEET**

8 / 8

Age-associated changes in lymphokine production**FIG. 7A****Restoration of IL-2 production by DHEA****FIG. 7B****SUBSTITUTE SHEET**

INTERNATIONAL SEARCH REPORT

International Application No. PCT/IIS90/05452

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): A61K 31/57

U.S. C1 514/179, 180

II. FIELDS SEARCHED

Minimum Documentation Searched ⁴

| Classification System | Classification Symbols |
|-----------------------|------------------------|
| U.S. | 514/179, 180 |

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁵

Database: DIALOG-FILE BIOCHEM

(See Attachment)

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴

| Category ⁶ | Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷ | Relevant to Claim No. ¹⁸ |
|-----------------------|--|-------------------------------------|
| X | BIOCHEMISTRY, Volume 27, issued 1988, No. 10, Matsushima et al. "Purification and Characterization of a Cytosolic 65-Kilodalton Phosphoprotein in Human Leukocytes whose Phosphorylation is Augmented by Stimulation with Interleukin 1". See abstract, Biosis No. 86034807. | 1,4,6,9 13-16,20 |
| X | JOURNAL OF IMMUNOLOGY, Volume 139, No. 10, issued 1987, Matsushima et al. "Phosphorylation of a Cytosolic 65-KDA Protein Induced By, Interleukin 1 In Glucocorticoid Pretreated Normal Human Peripheral Blood Mononuclear Leukocytes". See Abstract, Biosis No. 85027354. | 1,4,6,9 13-16,20 |

* Special categories of cited documents: ¹⁵

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search ²

30 November 1990

Date of Mailing of this International Search Report ²

18 JAN 1991

International Searching Authority ¹

ISA/US

Signature of Authorized Officer ³⁰


Andrew G. Rozycki

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

| Category * | Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷ | Relevant to Claim No ¹⁸ |
|------------|--|------------------------------------|
| 3 | IMMUNOBIOLOGY, Volume 161 No. 1-2, issued 1982, K.A. SMITH "T-Cell Growth Factor and Glucocorticoids: Opposing Regulatory Hormones in Neoplastic T-Cell Growth", See pages 157-173. | 1-4, 6 2, 13-16, 20 |
| 3 | THE JOURNAL OF IMMUNOLOGY Volume 143 No. 4, issued 15 August 1989, R.P. SCHLEIMER ET AL., "Regulation of Human Basophil Mediator Release by Cytokines I. Interaction with Antiinflammatory Steroids", See pages 1310-1317. | 1-4, 6, 9 13-16, 20 |

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

II. Field Searched (Keywords) Glucocorticoid, Dexamethasone, Corticoid Hydrocortisone, Cortisol, Corticosterone T-Cell, Lymphokine, Cytokine, Immunogenic, Interleukin, IL-4, Increase

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers because they relate to subject matter¹ not required to be searched by this Authority, namely:

2. Claim numbers, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹, specifically:

3. Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

(See Attachment)

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

1-4, 6, 9, 13-16, 20 as related to specie A only.

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.

Attachment To PCT/ISA /210

Observations Where Unity Of Invention Is Lacking

I. Claims 1-16 and 20 drawn to method for inducing the production of T-cell lymphokines.

II. Claims 17-19 drawn to a method for evaluating lymphokine production.

As well as the following distinct specie.

- A. glucocorticosterious
- B. 1, 25-dihydroxy vitamin D₃
- C. DHEA
- D. DHEA congerers